Use of Systemic Oral Fluoroquinolones in Canada

Project number: 
16-220
Approval date: 
Monday, December 5, 2016
Principal Investigator: 
Dormuth,Colin
Institution: 
University of British Columbia (UBC)
Funding Agency: 
Canadian Institutes of Health Research(CIHR)
Datasets requested: 
Consolidation registry (Ministry of Health)
Deaths (BC Vital Statistics Agency)
consolidation - census geocodes
MSP Registration & Premium Billing(BC Ministry of Health)
PharmaNet
Medical Services Plan (BC Ministry of Health)
Consolidation - demographic (Ministry of Health)
Hospital Separations (BC Ministry of Health)
Research objective: 

RESEARCH QUESTIONS

The overall objective is to assess utilization and indications for use of systemic oral fluoroquinolones in Canada since 2004. The BC CNODES site will apply these objectives to BC data only.

Specifically, the objectives are:
1. To assess utilization of each of the systemic oral fluoroquinolones in Canada (BC) since 2004.
2. To breakdown the utilization of each fluoroquinolone by dosage and duration of use.
3. To breakdown systemic oral fluoroquinolone use by prescriber group/specialty.
4. To determine the total number and percentage of prescriptions for fluoroquinolones issued to patients 5. To link an indication to each prescription for systemic oral fluoroquinolones.
6. To determine the antibiotics associated with diagnoses of ABS, and determine the proportion treated with fluoroquinolones.
7. To determine the antibiotics associated with diagnoses of ABECB-COPD, and determine the proportion treated with fluoroquinolones.
8. To determine the antibiotics associated with diagnoses of UTI, and determine the proportion treated with fluoroquinolones.
9. To assess the appropriateness of fluoroquinolone usage in specific disease groups (COPD, acute bacterial sinusitis, uncomplicated UTI) by comparing characteristics of patients who received a fluoroquinolone versus those who received recommended first-line therapy.
10. To use high dimensional propensity scores to allow comparisons between fluoroquinolone users and the users of guideline recommended first line therapy within three specific disease groups.

HYPOTHESES

1) Fluoroquinolone use in Canada (BC) is substantial and has increased since 2004.
2) A significant proportion of fluoroquinolone usage is for indications where either no antibiotic, or a different antibiotic, would be a more appropriate choice.


Page last revised: September 5, 2017